Stoke Therapeutics Inc (STOK)
12.02
+0.33
(+2.82%)
USD |
NASDAQ |
May 03, 16:00
12.00
-0.02
(-0.17%)
After-Hours: 20:00
Stoke Therapeutics Cash from Operations (TTM): -81.07M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -81.07M |
September 30, 2023 | -82.79M |
June 30, 2023 | -87.58M |
March 31, 2023 | -85.71M |
December 31, 2022 | -31.87M |
September 30, 2022 | -25.75M |
June 30, 2022 | -18.38M |
March 31, 2022 | -14.28M |
December 31, 2021 | -66.91M |
September 30, 2021 | -61.58M |
June 30, 2021 | -57.77M |
Date | Value |
---|---|
March 31, 2021 | -51.59M |
December 31, 2020 | -42.22M |
September 30, 2020 | -41.49M |
June 30, 2020 | -38.67M |
March 31, 2020 | -35.29M |
December 31, 2019 | -31.06M |
September 30, 2019 | -24.37M |
June 30, 2019 | -19.36M |
March 31, 2019 | -15.51M |
December 31, 2018 | -10.96M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-87.58M
Minimum
Jun 2023
-14.28M
Maximum
Mar 2022
-47.25M
Average
-41.49M
Median
Sep 2020
Cash from Operations (TTM) Benchmarks
NeuBase Therapeutics Inc | -14.78M |
iBio Inc | -18.89M |
Actinium Pharmaceuticals Inc | -39.63M |
Lixte Biotechnology Holdings Inc | -4.293M |
Fate Therapeutics Inc | -132.26M |